Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review

被引：6

作者：

Bhandari, Renu ^{[1
,2
]}

Ogeyingbo, Opemipo D. ^{[3
,4
,5
]}

Kareem, Roaa ^{[1
]}

Gyawali, Mallika

Venkatesan, Nanditha ^{[6
,7
]}

Ahmed, Rowan ^{[1
]}

Botleroo, Rinky A. ^{[8
]}

Elshaikh, Abeer O. ^{[6
]}

机构：

[1] Calif Inst Behav Neurosci & Psychol, Internal Med Family Med, Fairfield, CT 94534 USA

[2] Manipal Coll Med Sci, Internal Med, Kaski, Nepal

[3] Calif Inst Behav Neurosci & Psychol, Res, Fairfield, CT USA

[4] Walden Univ, Publ Hlth, Minneapolis, MN USA

[5] St James Sch Med, Internal Med, Park Ridge, IL USA

[6] Calif Inst Behav Neurosci & Psychol, Internal Med, Fairfield, CT USA

[7] All India Inst Med Sci, Internal Med, Raipur, Madhya Pradesh, India

[8] Calif Inst Behav Neurosci & Psychol, Med, Fairfield, CT USA

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 09期

关键词：

ulcerative colitis (uc); vedolizumab; inflammatory bowel disease; management; biological agent; MAINTENANCE THERAPY; INDUCTION; INFLIXIMAB; DIAGNOSIS; EXPOSURE; DISEASE;

D O I：

10.7759/cureus.17729

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ulcerative colitis (UC) is an inflammatory bowel disease and causes inflammation and ulcer of the colon. Vedolizumab is a newer biological agent with an inhibitory effect on a407 integrin approved for moderate to severe UC patients. Our study reviewed the clinical response, clinical remission, and mucosal healing of vedolizumab in moderate to severe UC management. Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a literature search in PubMed, Google Scholar, and Science Direct, and nine studies were included in the systematic review. At week six, vedolizumab showed a significant clinical response. At week 52, vedolizumah showed significant mucosal healing and clinical remission. The most commonly associated adverse effects are nasopharyngitis, oropharyngeal infection, and gastrointestinal infection. However, additional clinical trials and observational studies with longer follow-ups are required to study the efficacy and safety of the drug.

引用

页数：9

共 27 条

[1]

[Anonymous], 2014, Gastroenterol Hepatol (N Y), V10, P452

[2] Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis [J].

Bopanna, Sawan ;

Ananthakrishnan, Ashwin N. ;

Kedia, Saurabh ;

Yajnik, Vijay ;

Ahuja, Vineet .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (04) :269-276

[3] Side effects of corticosteroid therapy [J].

Buchman, AL .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2001, 33 (04) :289-294

[4] The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data [J].

Cohen, Russell D. ;

Bhayat, Fatima ;

Blake, Aimee ;

Travis, Simon .

JOURNAL OF CROHNS & COLITIS, 2020, 14 (02) :192-204

[5] Ulcerative colitis: diagnosis and management [J].

Collins, Paul ;

Rhodes, Jonathan .

BMJ-BRITISH MEDICAL JOURNAL, 2006, 333 (7563) :340-343

[6] Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis [J].

da Silva, Bruno Cesar ;

Lyra, Andre Castro ;

Rocha, Raquel ;

Santana, Genoile Oliveira .

WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (28) :9458-9467

[7]

Dave Maneesh, 2012, Gastroenterol Hepatol (N Y), V8, P29

[8] Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Publication with Expression of Concern) [J].

Dignass, Axel ;

Lindsay, James O. ;

Sturm, Andreas ;

Windsor, Alastair ;

Colombel, Jean-Frederic ;

Allez, Mathieu ;

D'Haens, Gert ;

D'Hoore, Andre ;

Mantzaris, Gerassimos ;

Novacek, Gottfried ;

Oeresland, Tom ;

Reinisch, Walter ;

Sans, Miquel ;

Stange, Eduard ;

Vermeire, Severine ;

Travis, Simon ;

Van Assche, Gert .

JOURNAL OF CROHNS & COLITIS, 2012, 6 (10) :991-1030

[9] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis [J].

Feagan, Brian G. ;

Schreiber, Stefan ;

Wolf, Douglas C. ;

Axler, Jeffrey L. ;

Kaviya, Arpeat ;

James, Alexandra ;

Curtis, Rebecca I. ;

Geransar, Parnia ;

Stallmach, Andreas ;

Ehehalt, Robert ;

Bokemeyer, Bernd ;

Khalid, Javaria Mona ;

O'Byrne, Sharon .

INFLAMMATORY BOWEL DISEASES, 2019, 25 (06) :1028-1035

[10] Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists [J].

Feagan, Brian G. ;

Rubin, David T. ;

Danese, Silvio ;

Vermeire, Severine ;

Abhyankar, Brihad ;

Sankoh, Serap ;

James, Alexandra ;

Smyth, Michael .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (02) :229-+

← 1 2 3 →